← Back to Search

Expressive Writing for Graft-versus-Host Disease (EXPRESS-C-GVHD Trial)

Q: Is enrollment for this clinical trial still available?

<p>According to clinicaltrials.gov, this particular trial is not presently seeking participants; the most recent update was on January 12th 2023. However, there are 166 other studies that currently require enrolment from potential subjects.</p>

Phase < 1

Waitlist Available

Led By Jennifer Choi

Research Sponsored by Northwestern University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 4 weeks

Awards & highlights

EXPRESS-C-GVHD Trial Summary

This trial investigates a new non-drug therapy for GVHD, a disease where donor cells attack the host body, to improve quality of life. The therapy, called expressive writing, involves writing and talking with others in a support group.

Who is the study for?

This trial is for adults over 18 with chronic cutaneous graft-versus-host disease (cGVHD), who can understand and sign consent, write or type, and have internet to join Zoom sessions. It's not for those with limited English skills.Check my eligibility

What is being tested?

The study tests expressive writing within a support group setting as a non-drug therapy to improve distress, systemic disease symptoms, and life quality in patients with skin-related GVHD.See study design

What are the potential side effects?

Since this intervention involves expressive writing rather than medication, traditional side effects are not expected. Participants may experience emotional discomfort while reflecting on their condition.

EXPRESS-C-GVHD Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 4 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~4 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in Dermatology Life Quality Index scores

Secondary outcome measures

Change in Short Form-36 scores

EXPRESS-C-GVHD Trial Design

1Treatment groups

Experimental Treatment

Group I: Expressive writing weekly sessionExperimental Treatment1 Intervention

Weekly, 1-hour sessions of creative writing, discussion and social support, in a group setting via videoconference for a total of 4 sessions.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Expressive Writing

2011

Completed Phase 3

~1990

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Northwestern UniversityLead Sponsor

1,592 Previous Clinical Trials

918,032 Total Patients Enrolled

Jennifer ChoiPrincipal InvestigatorNorthwestern University

Media Library

Expressive Writing Clinical Trial Eligibility Overview. Trial Name: NCT05694832 — Phase < 1

Graft-versus-Host Disease Research Study Groups: Expressive writing weekly session

Graft-versus-Host Disease Clinical Trial 2023: Expressive Writing Highlights & Side Effects. Trial Name: NCT05694832 — Phase < 1

Expressive Writing 2023 Treatment Timeline for Medical Study. Trial Name: NCT05694832 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment for this clinical trial still available?

"According to clinicaltrials.gov, this particular trial is not presently seeking participants; the most recent update was on January 12th 2023. However, there are 166 other studies that currently require enrolment from potential subjects."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Expressive Writing in GVHD

Jennifer Nam Choi, MD 2023. "Expressive Writing in GVHD". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05694832.

All > Gvhd